Skip to main content
. 2020 Nov 16;100(4):959–968. doi: 10.1007/s00277-020-04321-x

Table 3.

Characteristics of HMAClax therapy

Median time from REL to HMAClax, months (range) 1.8 (0.3–42.9)
Planned administration of VEN 21/28 d, n 13/19
Combination partner of VEN n
AZA/DAC, n 12/19#
AZA/DAC + DLI, n 11
Median number of cycles per patient 2 (1–19)
Total number of cycles, 90
Median duration of cycle 33 days (17–92)
Number of days with VEN 21 days (5–92)
Non-fatal tumor lysis syndrome 3 patients

REL relapse, HMA hypomethylating agent, HMAClax HMA + venetoclax, DLI donor lymphocyte infusion, VEN venetoclax